N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline

Summary

N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline (also known as POPHA or Compound Z-Pro-Prolinal analogue in some literature, most commonly referenced as the prolyl endopeptidase inhibitor Eurystatin A or a close structural analogue) is a naturally-derived or synthetic epoxide dipeptide that potently and irreversibly inhibits prolyl oligopeptidase. It has been used extensively as a research tool to study the role of POP in neuropeptide metabolism, cognition, and neurological disorders. No approved clinical indication exists; it is used primarily in in vitro and animal studies.

Mechanism of Action

Irreversible inhibition of prolyl endopeptidase (prolyl oligopeptidase, POP/PREP) via covalent modification of the active-site serine residue by the epoxide electrophile; reduces cleavage of proline-containing neuropeptides such as substance P, vasopressin, and thyrotropin-releasing hormone

Routes of Administration

Goals & Uses

• Cognitive/memory researchNeuroscience ResearchModerate
• Anti-amnesic investigationInvestigational CNSLow
• Prolyl oligopeptidase inhibitionEnzyme Inhibition / Research ToolHigh
• Neuropeptide metabolism modulationNeuropharmacologyModerate

Contraindications

• Human therapeutic useRegulatory/safetyHigh

Adverse Effects

• Non-selective protease inhibition at high concentrationsOff Target EffectUnknown
• Irreversible enzyme inactivationPharmacodynamicUnknown

Drug Interactions

• Other serine protease inhibitorsLow

Population Constraints

• HumansRegulatory / SafetyAbsolute
• Pregnant animalsReproductiveRelative

Regulatory Status

• European UnionUnapprovedResearch compound only; not authorized by EMA
• United StatesUnapprovedResearch compound only; no FDA approval or IND on record
• United KingdomUnapprovedResearch compound only; not authorized by MHRA

Not approved for human therapeutic use in any jurisdiction. Used as a pharmacological research tool. No IND or clinical trial registration identified for this specific compound.

Evidence & Sources

No sources recorded yet.